abstract |
The present invention relates to a dose form of the Factor Xa inhibitor, comprising apixaban in an improved solubility form, wherein the dose form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, thrombosis of deep veins and acute coronary syndrome, with this dosage form. |